alpha-MSH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-30. Anything still debated is marked as such rather than presented as settled.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
The units use strontium-90, and a larger number of such units have been deployed both on the ground and on the ocean floor than have been used on spacecraft, with public regulatory documents suggesting that the US had deployed at least 100–150 during the 1970s and 1980s. In the past, small "plutonium cells" (very small 238Pu-powered RTGs) were used in implanted heart pacemakers to ensure a very long "battery life". As of 2004, about ninety were still in use. By the end of 2007, the number was reported to be down to just nine. The Mound Laboratory Cardiac Pacemaker program began on 1 June 1966, in conjunction with NUMEC. The program was cancelled in 1972, when it was recognized that the heat source would not remain intact during cremation and there was no way to completely ensure that the units would not be cremated with their users' bodies.
Despite being raised as a communicant of the Catholic Church, on January 19, 2016, Duterte clarified that he had not attended Mass for quite some time already since he deemed it incompatible with his mayoral responsibilities: "If I listened to the Ten Commandments or to the priests," said Duterte, "I would not be able to do anything as a mayor." Duterte has described himself as Christian in 2016 and "spiritual" in 2018, expressing that he "can't accept" Catholicism or organized religion but also that he is neither an atheist nor an agnostic. He has referred to God as Allah and has been quoted as saying: "a part of me which is Islam". During his presidency, Duterte and the Catholic Church in the Philippines exchanged frequent criticisms. In response to the rising death toll in Duterte's war on drugs, the Catholic Bishops' Conference of the Philippines (CBCP) in February 2017 issued a strongly worded pastoral letter which was read in church services; the letter highlighted that "[killing] is considered as normal", and "to consent and keep silent in front of evil is to be an accomplice to it". Duterte later lambasted Catholic bishops, telling them "not use the pulpit", reviling them as "sons of bitches", remarking that some of them are gay, and urging street bums to rob and kill them. Notable among the bishops Duterte criticized was Caloocan Bishop Pablo Virgilio David, a vocal critic of the Duterte administration's war on drugs.
Osteoarthritis is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone. A form of arthritis, it is believed to be the fourth leading cause of disability in the world, with an estimated 240 million people worldwide having activity-limiting osteoarthritis. The most common symptoms are joint pain and stiffness. Usually the symptoms progress slowly over years. Other symptoms may include joint swelling, decreased range of motion, and, when the back is affected, weakness or numbness of the arms and legs. The most commonly involved joints are the two near the ends of the fingers and the joint at the base of the thumbs, the knee and hip joints, and the joints of the neck and lower back. The symptoms can interfere with work and normal daily activities. Unlike some other types of arthritis, only the joints, not internal organs, are affected. Possible causes include previous joint injury, abnormal joint or limb development, and inherited factors. Risk is greater in those who are overweight, have legs of different lengths, or have jobs that result in high levels of joint stress. Osteoarthritis is believed to be caused by mechanical stress on the joint and low grade inflammatory processes. It develops as cartilage is lost and the underlying bone becomes affected. As pain may make it difficult to exercise, muscle loss may occur. Diagnosis is typically based on signs and symptoms, with medical imaging and other tests used to support or rule out other problems.
Nicotinamide adenine dinucleotide consists of two nucleosides joined by pyrophosphate. The nucleosides each contain a ribose ring, one with adenine attached to the first carbon atom (the 1' position) (adenosine diphosphate ribose) and the other with nicotinamide at this position.
=== Tolerance === Clinical research has not demonstrated drug tolerance, a reduction in wakefulness-promoting and anti-fatigue effects, as a common outcome, even with therapeutic use extending up to 40 weeks. However, long-term use can lead to tolerance in some individuals, necessitating higher doses to maintain efficacy. People with current or past substance addictions and those with a family history of addiction are at higher risk. The underlying mechanisms, which may involve dopamine and norepinephrine pathways, are not fully understood. Tolerance appears more likely with off-label use for cognitive enhancement than with therapeutic use for narcolepsy, where effectiveness does not usually diminish with prolonged treatment.
Sources: en.wikipedia.org
==== Effects in animals and humans ==== According to Alexander Shulgin in PiHKAL, phenethylamine is completely inactive in humans at doses of up to 1,600 mg orally and 50 mg intravenously. This can be attributed to its extremely rapid metabolic breakdown rather than pharmacodynamic inactivity. Although exogenous phenethylamine on its own is inactive, its metabolism can be strongly inhibited and it can thereby become active, showing psychostimulant effects, when combined with a monoamine oxidase inhibitor (MAOI), specifically monoamine oxidase B (MAO-B) inhibitors like selegiline. Oral L-phenylalanine (a precursor of phenethylamine) and/or phenethylamine itself in combination with selegiline has been studied in the treatment of depression and has been reported to be effective. Misuse of phenethylamine in combination with selegiline has also been reported. The LD50Tooltip median lethal dose values of phenethylamine include 175 mg/kg i.p. in mice, 320 mg/kg s.c. in mice, 100 mg/kg i.v. in mice, 100 mg/kg parenterally in mice, 39 mg/kg intracervically in mice, and 200 mg/kg i.p. in guinea pigs. Its LDLo values include 800 mg/kg p.o. in rats, 100 mg/kg i.p. in rats, 450 μg/kg s.c. in rats, and 300 mg/kg via an unspecified route in mice.
=== Pharmacokinetics === The metabolism of 4-HO-MET has been studied. In vitro experiments using pooled human liver microsomes identified twelve metabolites. Four metabolites were detected in vivo from human urine, of which two were detected in vitro.
Elaunin (Greek verb ἐλαύνω "I steer") is a component of elastic fibers formed from deposition of elastin between oxytalan fibers. It is found in the periodontal ligament and the connective tissue of the dermis, particularly in association with sweat glands.
== External links == hepcidin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Intrinsic LifeSciences - Hepcidin Research Facility, The BioIron Company Hepcidinanalysis.com - Service for Hepcidin measurements: Scientific Research, Patients and Clinical Trials Protein Data Bank Page PDBe-KB provides an overview of all the structure information available in the PDB for Human Hepcidin
Sources: en.wikipedia.org
== Gaiden 1 == The Gaiden 1 (外伝1) series, released between February and September 1998, adapts the short stories "Silver-White Valley" (episodes 1–4), "Dreams of the Morning, Songs of the Night" (5–8), "Dishonour", and the novel A Hundred Billion Stars, a Hundred Billion Lights (9–12). Both Gaidens are prequels to the main story, depicting events that take place before season 1 of the show.
=== UK === The UK site is provided by the Association for Laboratory Medicine. It provides contextual hyperlinks from individual reports to the appropriate support information on the site. This is in routine use from one of the major suppliers of clinical informations systems in primary care and from the English NHS app.
When two drugs have the same bioavailability, they are said to be biological equivalents or bioequivalents. The concept of bioequivalence is important since it is currently used as a yardstick in the authorization of generic drugs in many countries.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.